Carla Strina

642 total citations
25 papers, 362 citations indexed

About

Carla Strina is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Carla Strina has authored 25 papers receiving a total of 362 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 12 papers in Cancer Research and 8 papers in Molecular Biology. Recurrent topics in Carla Strina's work include Breast Cancer Treatment Studies (9 papers), HER2/EGFR in Cancer Research (8 papers) and Advanced Breast Cancer Therapies (4 papers). Carla Strina is often cited by papers focused on Breast Cancer Treatment Studies (9 papers), HER2/EGFR in Cancer Research (8 papers) and Advanced Breast Cancer Therapies (4 papers). Carla Strina collaborates with scholars based in Italy, United Kingdom and United States. Carla Strina's co-authors include Daniele Generali, Adrian L. Harris, Daniele Andreis, Giovanni Allevi, Jacek Capala, Ioannis Roxanis, Alberto Bottini, Gabriela Krämer-Marek, Sergio Aguggini and Esther Bridges and has published in prestigious journals such as Scientific Reports, British Journal of Cancer and Annals of Oncology.

In The Last Decade

Carla Strina

23 papers receiving 355 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Carla Strina Italy 10 242 125 107 71 59 25 362
Fernando Ortiz-Martínez Spain 9 220 0.9× 120 1.0× 221 2.1× 77 1.1× 78 1.3× 12 419
André Mansinho Portugal 11 220 0.9× 101 0.8× 149 1.4× 109 1.5× 50 0.8× 36 400
S. G. Shering Ireland 8 200 0.8× 140 1.1× 175 1.6× 34 0.5× 48 0.8× 11 484
Malgorzata Banys-Paluchowski Germany 16 270 1.1× 249 2.0× 131 1.2× 96 1.4× 29 0.5× 46 519
Angela Cramer United Kingdom 10 287 1.2× 176 1.4× 198 1.9× 53 0.7× 83 1.4× 19 506
Anita Welk Germany 6 175 0.7× 67 0.5× 154 1.4× 51 0.7× 24 0.4× 7 321
Katrin Almstedt Germany 12 270 1.1× 119 1.0× 125 1.2× 95 1.3× 43 0.7× 33 403
Sheila J. Dearing United Kingdom 5 260 1.1× 112 0.9× 169 1.6× 61 0.9× 43 0.7× 7 367
L. Edwards Australia 7 142 0.6× 73 0.6× 139 1.3× 39 0.5× 35 0.6× 7 363
Zhanhuai Wang China 12 243 1.0× 170 1.4× 231 2.2× 68 1.0× 38 0.6× 24 501

Countries citing papers authored by Carla Strina

Since Specialization
Citations

This map shows the geographic impact of Carla Strina's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carla Strina with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carla Strina more than expected).

Fields of papers citing papers by Carla Strina

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carla Strina. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carla Strina. The network helps show where Carla Strina may publish in the future.

Co-authorship network of co-authors of Carla Strina

This figure shows the co-authorship network connecting the top 25 collaborators of Carla Strina. A scholar is included among the top collaborators of Carla Strina based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carla Strina. Carla Strina is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Schettini, Francesco, Silvana Saracchini, Serena Corsetti, et al.. (2024). Prediction of response to neoadjuvant chemotherapy by MammaTyper® across breast cancer subtypes: A retrospective cross-sectional study. The Breast. 76. 103753–103753. 1 indexed citations
2.
Vernieri, Claudio, Francesca Ligorio, Claudia De Angelis, et al.. (2023). 352TiP Neoadjuvant chemo-immunotherapy plus/minus fasting-like approach in stage II-III triple-negative breast cancer patients: The phase II randomized BREAKFAST-2 trial. Annals of Oncology. 34. S322–S323. 2 indexed citations
3.
Schettini, Francesco, Maria Valeria De Bonis, Carla Strina, et al.. (2023). Computational reactive–diffusive modeling for stratification and prognosis determination of patients with breast cancer receiving Olaparib. Scientific Reports. 13(1). 11951–11951.
4.
Schettini, Francesco, Alessandra Fontana, Carla Strina, et al.. (2023). Faecal microbiota composition is related to response to CDK4/6-inhibitors in metastatic breast cancer: A prospective cross-sectional exploratory study. European Journal of Cancer. 191. 112948–112948. 9 indexed citations
5.
D’Angelo, Alberto, Fabiola Giudici, Robert Chapman, et al.. (2022). Clinico-Immunological Effects of a Single-Agent CDK4/6 Inhibitor in Advanced HR+/HER2− Breast Cancer Based on a Window of Opportunity Study. Current Issues in Molecular Biology. 44(9). 4255–4267.
6.
Schettini, Francesco, Navid Sobhani, Tiziana Triulzi, et al.. (2020). Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study. Breast Cancer Research and Treatment. 184(2). 421–431. 12 indexed citations
7.
Giudici, Fabiola, Carla Strina, Ottavia Bernocchi, et al.. (2020). ΔKi67 proliferation index as independent predictive and prognostic factor of outcome in luminal breast cancer: data from neoadjuvant letrozole-based treatment. Tumor Biology. 42(6). 2904802933–2904802933. 11 indexed citations
8.
Corona, Silvia Paola, Giandomenico Roviello, Carla Strina, et al.. (2019). Efficacy of extended aromatase inhibitors for hormone-receptor–positive breast cancer: A literature-based meta-analysis of randomized trials. The Breast. 46. 19–24. 9 indexed citations
9.
Generali, Daniele, Silvia Paola Corona, Lajos Pusztai, et al.. (2018). Benefit of the addition of hormone therapy to neoadjuvant anthracycline-based chemotherapy for breast cancer: comparison of predicted and observed pCR. Journal of Cancer Research and Clinical Oncology. 144(3). 601–606. 3 indexed citations
10.
Milani, Manuela, Sergio Venturini, Simone Bonardi, et al.. (2017). Hypoxia-related biological markers as predictors of epirubicin-based treatment responsiveness and resistance in locally advanced breast cancer. Oncotarget. 8(45). 78870–78881. 10 indexed citations
11.
Roviello, Giandomenico, Manuela Milani, Maria Rosa Cappelletti, et al.. (2016). A Phase Ib Open-Label Study to Assess the Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-Negative Breast Cancers. Clinical Breast Cancer. 16(3). e57–e59. 4 indexed citations
12.
Andreis, Daniele, Giovanni Allevi, Sergio Aguggini, et al.. (2016). Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancer. The Breast. 29. 55–61. 8 indexed citations
13.
Generali, Daniele, Mara Ardine, Carla Strina, et al.. (2015). Neoadjuvant Treatment Approach: The Rosetta Stone for Breast Cancer?. JNCI Monographs. 2015(51). 32–35. 6 indexed citations
14.
Generali, Daniele, Alfredo Berruti, Laura Zanotti, et al.. (2015). Effect of Primary Letrozole Treatment on Tumor Expression of mTOR and HIF-1  and Relation to Clinical Response. JNCI Monographs. 2015(51). 64–66. 6 indexed citations
15.
Generali, Daniele, Gabriela Krämer-Marek, Merel Gijsen, et al.. (2014). ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer. Oncotarget. 5(16). 6633–6646. 68 indexed citations
16.
Koukourakis, Michael I., Alexandra Giatromanolaki, Alberto Bottini, et al.. (2014). Prospective neoadjuvant analysis of PET imaging and mechanisms of resistance to Trastuzumab shows role of HIF1 and autophagy. British Journal of Cancer. 110(9). 2209–2216. 18 indexed citations
17.
Generali, Daniele, Gabriela Krämer-Marek, Merel Gijsen, et al.. (2014). Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer. Oncotarget. 5(15). 5934–5949. 50 indexed citations
18.
Allevi, Giovanni, Carla Strina, Daniele Andreis, et al.. (2013). Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer. British Journal of Cancer. 108(8). 1587–1592. 46 indexed citations
19.
Strina, Carla, et al.. (2009). Bone Metastases from Primary Cardiac Sarcoma: Case Report. Tumori Journal. 95(2). 251–253. 9 indexed citations
20.
Ferrari, Vittorio, Francesca Valcamonico, Vito Amoroso, et al.. (2005). Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial. Cancer Chemotherapy and Pharmacology. 57(2). 185–190. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fernando Ortiz-Martínez Breakdown of academic impact, for papers by André Mansinho Breakdown of academic impact, for papers by S. G. Shering Breakdown of academic impact, for papers by Malgorzata Banys-Paluchowski Breakdown of academic impact, for papers by Angela Cramer Breakdown of academic impact, for papers by Anita Welk Breakdown of academic impact, for papers by Katrin Almstedt Breakdown of academic impact, for papers by Sheila J. Dearing Breakdown of academic impact, for papers by L. Edwards Breakdown of academic impact, for papers by Zhanhuai Wang
Rankless by CCL
2026